LifeMD (NASDAQ:LFMD) Trading Down 4.2% - What's Next?

Key Points

• Shares fell 4.2% intraday to as low as $3.32 and last traded at $3.43 on roughly 755,877 shares, a 52% decline from average daily volume.
• Analysts' consensus is a Moderate Buy (seven Buys, one Hold, one Sell) with an average price target of $9.14.
• LifeMD missed the quarter with EPS of $(0.04) versus $(0.01) expected and revenue of $46.87M versus $48.57M expected; analysts project -$0.56 EPS for the current fiscal year.

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) were down 4.2% during mid-day trading on Tuesday . The company traded as low as $3.32 and last traded at $3.43. Approximately 755,877 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 1,562,775 shares. The stock had previously closed at $3.58.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LFMD shares. Wall Street Zen upgraded shares of LifeMD from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Zacks Research upgraded shares of LifeMD from a "strong sell" rating to a "hold" rating in a research note on Friday, December 19th. Weiss Ratings restated a "sell (e+)" rating on shares of LifeMD in a research note on Friday, March 27th. BTIG Research reaffirmed a "buy" rating and issued a $10.00 target price on shares of LifeMD in a report on Tuesday, March 10th. Finally, HC Wainwright upped their target price on shares of LifeMD from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, March 11th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $9.14.

LifeMD Trading Down 4.2%

The company's fifty day moving average price is $3.34 and its two-hundred day moving average price is $4.24. The firm has a market cap of $164.54 million, a P/E ratio of 13.19 and a beta of 1.77.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.03). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The firm had revenue of $46.87 million during the quarter, compared to the consensus estimate of $48.57 million. On average, analysts predict that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently added to or reduced their stakes in LFMD. Caitong International Asset Management Co. Ltd bought a new stake in LifeMD during the 4th quarter worth about $36,000. Magnus Financial Group LLC bought a new stake in LifeMD during the 4th quarter worth about $41,000. Jain Global LLC bought a new stake in LifeMD during the 4th quarter worth about $45,000. Quarry LP bought a new stake in LifeMD during the 3rd quarter worth about $52,000. Finally, Tower Research Capital LLC TRC grew its holdings in LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. Institutional investors own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company's core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD's service portfolio spans several specialty areas, including men's health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.